9^th International Summit on Clinical Microbiology October 08-09, 2018 Zurich, Switzerland

Henry M. Sobell completed his studies at Brooklyn Technical High School (1948-1952), Columbia College (1952-1956), and the University of Virginia School of Medicine (1956-1960). Instead of practicing clinical medicine, he then went to the Massachusetts Institute of Technology (MIT) to join Professor Alexander Rich in the Department of Biology (1960-1965), where, as a Helen Hay Whitney Postdoctoral Fellow, he learned the technique of single crystal X-ray analysis. He then joined the Chemistry Department at the University of Rochester, having been subsequently jointly appointed to both the Chemistry and Molecular Biophysics departments (the latter at the University of Rochester School of Medicine and Dentistry), becoming a full tenured Professor in both departments.

Chemistry and Molecular Biophysics

Dr. Iwona Beech is an internationally recognized expert in the field of biofilm-influenced corrosion and biofouling. She has over 24 years of research experience in studying fundamental and applied aspects of biocorrosion of metallic and biodeteriotration of non-metallic materials in both freshwater and marine environments and an extensive history of collaborations with Academia and Industry worldwide, including oil, gas and shipping industries and the navy.

Uses of immuno and molecular biology techniques and advanced mass spectrometry methods to understand the importance of biofilm community structure and involvement of bacterial metabolites

Ananda M. Chakrabarty, Ph.D., is a Distinguished University Professor at the University of Illinois College of Medicine at Chicago. While working at the Research & Development Center at General Electric Company in Schenectady, New York, he was awarded the ‘Scientist of the Year’ award in 1975 by Industrial Research Organization of the United States. This work led to the development of a genetically-manipulated microorganism that was the subject matter of a landmark decision from the Supreme Court of the United States that genetically engineered life forms are patentable. Dr. Chakrabarty has served as a consultant with the United Nations and was the founding member of a UNIDO Committee that proposed the establishment of the International Centre for Genetic Engineering & Biotechnology (ICGEB) based in Trieste, Italy, New Delhi, India, and Cape Town, South Africa. Dr. Chakrabarty has been a member of the Panel of Scientific Advisors, later called Council of Scientific Advisors, of ICGEB since its very inception. Dr. Chakrabarty has also been a member of the International Advisory Board of Chulabhorn Research Institute in Thailand, which is headed by the Princess Chulabhorn of Thailand.He was awarded the civilian Padma Shri award by the Government of India in 2007.

Dr. Chakrabarty’s current research involves development of anticancer agents from microbial sources. As a Co-Founder of CDG Therapeutics Inc, he has developed candidate anticancer drugs such as p28, which has shown very little toxicity in 15 advanced stage cancer patients but significant beneficial effect, including partial and complete regression of tumors that were refractory to conventional drugs, in phase I human clinical trials in Chicago.

Co-founder and CEO of leadXpro AG, a spin-out of the Paul Scherrer Institute (ETH domain, Switzerland) dedicated to discovery of new therapeutics using structure based drug discovery with a focus on membrane protein targets,20 years at Roche research from 1995 to 2015, Global Head and Principle Leader of discovery technologies with responsibility for structure based drug discovery, protein science, assay development and HTS, corporate compound library, stem cell platform,Guest Professor at the University of Basel in structural biology, author of >75 paper and lecturer at conferences, 8 patents in areas of technology, discovery and formulation of drug substances,Study of physics, biochemistry, PhD in structural biology at EMBL Hamburg & Charité Berlin, Germany, postdoc at Biozentrum, University of Basel, Switzerland

Discovery of new therapeutics using structure based drug discovery with a focus on membrane protein targets

Juliana Chiruta has completed her PhD in the Department of Immunology and Microbiology and at the Department of Chemistry from The University of Adelaide. She is currently employed as a Senior Member of the professional staff in the Faculty of Health, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Australia. She is an Associate Fellow of Higher Education Academy (UK) and a member of Higher Education Research Network

Immunology and Microbiology

Serves Laboratory of Environmental Biotechnologies at SRPA “Chemical Synthesis and Biotechnologies” in Belarus

Enviromental science

Neveen Saleh has completed her PhD at age of 34 years from Ain Shams University and has got postdoctoral studies from Massachusetts, Amherst (UMASS) University in Nanotechnology, Chemistry department. She is now amicrobiological researcher in National organization for drug control and research. She has published more than 10 papers in reputed journals.

Antibiotics

Mahasen Wadi completed the PhD from AL Neelain University , Medical Microbiology. Faculty of Medical Laboratory Sciences 2010 Khratoum Sudan. MSc. University of Khartoum, Sudan. Medical Microbiology & Pharmacology 1987. She joined work at Dar ALUloom University, College of Medicine, Riyadh , Saudi Arabia August 2014, She Worked at the central research laboratory Khartoum , Sudan. She joined work at King Saud University, Saudi Arabia, Riyadh 1988, Department of Clinical Laboratory Science, and Medical Microbiology

antimicrobial activity of Sudanese bee honey.

Ananda M. Chakrabarty, Ph.D., is a Distinguished University Professor at the University of Illinois College of Medicine at Chicago. While working at the Research & Development Center at General Electric Company in Schenectady, New York, he was awarded the ‘Scientist of the Year’ award in 1975 by Industrial Research Organization of the United States. This work led to the development of a genetically-manipulated microorganism that was the subject matter of a landmark decision from the Supreme Court of the United States that genetically engineered life forms are patentable. Dr. Chakrabarty has served as a consultant with the United Nations and was the founding member of a UNIDO Committee that proposed the establishment of the International Centre for Genetic Engineering & Biotechnology (ICGEB) based in Trieste, Italy, New Delhi, India, and Cape Town, South Africa. Dr. Chakrabarty has been a member of the Panel of Scientific Advisors, later called Council of Scientific Advisors, of ICGEB since its very inception. Dr. Chakrabarty has also been a member of the International Advisory Board of Chulabhorn Research Institute in Thailand, which is headed by the Princess Chulabhorn of Thailand.He was awarded the civilian Padma Shri award by the Government of India in 2007.

Dr. Chakrabarty’s current research involves development of anticancer agents from microbial sources. As a Co-Founder of CDG Therapeutics Inc, he has developed candidate anticancer drugs such as p28, which has shown very little toxicity in 15 advanced stage cancer patients but significant beneficial effect, including partial and complete regression of tumors that were refractory to conventional drugs, in phase I human clinical trials in Chicago.